Appendix II — E — Decisions Cited — E
Ninth Edition, Revision 01.2024
[ Editor Note: Opinions of the Patent Trial and Appeal Board or its predecessor organizations (Board) made available to the public after the Board first published Standard Operating Procedure 2 in 1994 (addressing the publication of Board opinions and the designation of such opinions as precedential) that (1) expressly indicate that the opinion is binding precedent of the Board or (2) are identified as binding precedent on the Board’s Precedential opinion website ( www.uspto.gov/patents-application-process/appealing -patent-decisions/decisions-and-opinions/precedential ) are precedential and binding authority. Prior to 1994, a decision by the Board was considered binding on panels of the Board only if the opinion was authorized by the Board to be published. See Ex parte Holt, 19 USPQ2d 1211 (Bd.Pat. App. & Int. 1991).]
Editor Note: When possible, parallel citations to the United States Reports or Federal Reporter and the United States Patent Quarterly (USPQ) are provided and include pinpoint pages, if appropriate. However, decisions of the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit published after July 11, 2022, no longer contain a pinpoint page for the USPQ citations.
E-Pass Techs., Inc. v. 3Com Corp., 343 F.3d 1364, 67 USPQ2d 1947 (Fed. Cir. 2003) 2111.01
East Chicago Machine Tool Corp. v. Stone Container Corp., 181 USPQ 744 (N.D. Ill. 1974) 2012
Eastwood, Ex parte, 163 USPQ 316 (Bd. App. 1968) 2173.05(b)
Eaton v. Evans, 204 F.3d 1094, 53 USPQ2d 1696 (Fed. Cir. 2000) 2138.05
Echerd, In re, 471 F.2d 632, 176 USPQ 321 (CCPA 1973) 1207.03(a)
Eckel, In re, 393 F.2d 848, 157 USPQ 415 (CCPA 1968) 804.02
Ecolab, Inc. v. FMC Corp., 569 F.3d 1335, 91 USPQ2d 1225 (Fed. Cir. 2009) 2143
Ecolochem, Inc. v. S. California Edison Co., 227 F.3d 1361, 56 USPQ2d 1065 (Fed. Cir. 2000) 2141.03
Edge, In re, 359 F.2d 896, 149 USPQ 556 (CCPA 1966) 2144.04
Edgerton v. Kingsland, 168 F.2d 121, 75 USPQ 307 (D.C. Cir. 1947) 2190
Edwards, In re, 568 F.2d 1349, 196 USPQ 465 (CCPA 1978) 2138.05
Edwards v. Strazzabosco, 58 USPQ2d 1836 (Bd. Pat. App. & Inter. 2001 - xx/xxx,xxxx) 2305
Egbert v. Lippmann, 104 U.S. 333 (1881) 2133.03(a)
Egenera, Inc. v Cisco Sys., Inc., 972 F.3d 1367, 2020 USPQ2d 10997 (Fed. Cir. 2020) 1481.02
Eggan, Ex parte, 1911 C.D. 213, 172 O.G. 1091 (Comm’r Pat. 1911) 403.01 , 403.02
Egyptian Goddess Inc. v. Swissa Inc., 543 F.3d 665, 88 USPQ2d 1658 (Fed. Cir. 2008) (en banc) 1504.02
Ehrreich, In re, 590 F.2d 902, 200 USPQ 504 (CCPA 1979) 2129 , 2172 , 2411.01
Eibel Process Co. v. Minnesota & Ontario Paper Co., 261 U.S. 45 (1923) 2106.05 , 2106.05(b) , 2173.05(b)
E.I. du Pont de Nemours & Co. v. Berkley and Co., 620 F.2d 1247, 205 USPQ 1 (8th Cir. 1980) 2107.01
E.I. du Pont de Nemours & Co. v. Phillips Petroleum Co., 849 F.2d 1430, 7 USPQ2d 1129 (Fed. Cir. 1988) 2138
E.I. du Pont de Nemours & Co. v. Synvina C.V, 904 F.3d 996, 128 USPQ2d 1193 (Fed. Cir. 2018) 2144.05
Eickmeyer, In re, 602 F.2d 974, 202 USPQ 655 (CCPA 1979) 715.05 , 715.07
Eisai Co. Ltd. v. Dr. Reddy’s Labs., Ltd., 533 F.3d 1353, 87 USPQ2d 1452 (Fed. Cir. 2008) 2143
Eiselstein v. Frank, 52 F.3d 1035, 34 USPQ2d 1467 (Fed. Cir. 1995) 1302.01
Ekenstam, In re, 256 F.2d 321, 118 USPQ 349 (CCPA 1958) 2126 , 2126.01 , 2132 , 2152.02(a)
Elan Corp., PLC v. Andrx Pharms. Inc., 366 F.3d 1336, 70 USPQ2d 1722 (Fed. Cir. 2004) 2133.03(b)
Elan Pharm., Inc. v. Mayo Foundation For Medical and Education Research, 346 F.3d 1051, 68 USPQ2d 1373 (Fed. Cir. 2003) 2121.01
Electric Power Group, LLC v. Alstom S.A., 830 F.3d 1350, 119 USPQ2d 1739 (Fed. Cir. 2016) 2106.04(a)(1) , 2106.05(a) , 2106.05(f) , 2106.05(g) , 2106.05(h)
Electric Storage Battery Co. v. Shimadzu, 307 U.S. 5, 41 USPQ 155 (1938) 2133.03(b)
Electromotive Div. of Gen. Motors Corp. v. Transportation Sys. Div. of Gen. Elec. Co., 417 F.3d 1203, 75 USPQ2d 1650 (Fed. Cir. 2005) 2133.03(e)(4) , 2133.03(e)(5)
Elekta Ltd. v. ZAP Surgical Sys., Inc., 81 F.4th 1368, 2023 USPQ2d 1100 (Fed. Cir. 2023) 2143.02
Eli Lilly & Co. v. Apotex, Inc., 837 Fed. Appx. 780, 2020 USPQ2d 11531 (Fed. Cir. 2020) 2173.05(u)
Eli Lilly & Co. v. Bd. of Regents of the Univ. of Wa., 334 F.3d 1264, 67 USPQ2d 1161 (Fed. Cir. 2003) 2301.03
Eli Lilly & Co. v. Barr Laboratories, Inc., 251 F.3d 955, 58 USPQ2d 1869 (Fed. Cir. 2001) 804 , 804.02 , 1490 , 2144.08 , 2165 , 2165.01
Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 15 USPQ2d 1121 (1990) 2750
Eli Lilly & Co. v. Teva Parenteral Meds., 845 F.3d 1357, 121 USPQ2d 1277 (Fed. Cir. 2017) 2173.05(h)
Eli Lilly & Co. v. Teva Pharms. Int’l GmbH, 8 F.4th 1331, 2021 USPQ2d 862 (Fed. Cir. 2021) 2143.02
Eli Lilly & Co. v. Zenith Goldline Pharms., Inc., 471 F.3d 1369, 81 USPQ2d 1324 (Fed. Cir. 2006) 2152.02(b)
Eli Lilly, In re, 902 F.2d 943, 14 USPQ2d 1741 (Fed. Cir. 1990) 716.01(d) , 716.02(b) , 716.02(c) , 2141 , 2142 , 2144 , 2144.08
Elliott, Ex parte, 1904 C.D.103, 109 O.G. 1337 (Comm’r Pat. 1904) 608.02(g)
Ellis, In re, 476 F.2d 1370, 177 USPQ 526 (CCPA 1973) 2141.01(a)
Elmwood Liquid Prod., Inc. v. Singleton Packing Corp., 328 F. Supp 974, 170 USPQ 398 (M.D. Fla. 1971) 2004
Elsner, In re, 381 F.3d 1125, 72 USPQ2d 1038 (Fed. Cir. 2004) 2121.03
Eltgroth, In re, 419 F.2d 918, 164 USPQ 221 (CCPA 1970) 2107.01
EmeraChem Holdings, LLC v. Volkswagen Grp. of Am., Inc., 859 F.3d 1341, 123 USPQ2d 1146 (Fed. Cir. 2017) 715.01(a) , 715.01(c) , 716.10 , 2155.01
Emerson Elec. Co. v. Davoil, Inc., 88 F.3d 1051, 39 USPQ2d 1474 (Fed. Cir. 1996) 2254
Emert, In re, 124 F.3d 1458, 44 USPQ2d 1149 (Fed. Cir. 1997) 804
Emery v. Ronden, 188 USPQ 264 (Bd. Pat. Inter. 1974) 2138.06
Encyclopaedia Britannica, Inc. v. Alpine Elecs., Inc., 355 Fed. App'x. 389 (Fed. Cir. 2009) 2181
Enfish, LLC v. Microsoft Corp., 822 F.3d 1327, 118 USPQ2d 1684 (Fed. Cir. 2016) 2106 , 2106.04 , 2106.04(a) , 2106.04(a)(1) , 2106.05 , 2106.05(a) , 2106.05(d) , 2106.05(f) , 2106.06(b)
Engelhardt v. Judd, 369 F.2d 408, 151 USPQ 732 (CCPA 1966) 2138.03 , 2138.05
Envirco Corp. v. Clestra Cleanroom, Inc., 209 F.3d 1360, 54 USPQ2d 1449 (Fed. Cir. 2000) 2181
Environ Prods., Inc. v. Total Containment, Inc., 43 USPQ2d 1288 (E.D. Pa. 1997) 2001.06(c)
Environmental Designs, Ltd. v. Union Oil Co., 713 F.2d 693, 218 USPQ 865 (Fed. Cir. 1983) 716.04 , 716.05 , 2141 , 2141.03
Envirotech Corp. v. Westech Eng’g, Inc., 904 F.2d 1571, 15 USPQ2d 1230 (Fed. Cir. 1990) 2133.03(b)
Enzo Biochem, Inc., v. Applera Corp., 599 F.3d 1325, 94 USPQ2d 1321 (Fed. Cir. 2010) 2173.05(b)
Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362, 52 USPQ2d 1129 (Fed. Cir. 1999) 2164.06(b)
Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956, 63 USPQ2d 1609 (Fed. Cir. 2002) 2161.01 , 2163 , 2163.05 , 2402
Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc., 928 F.3d 1340 (Fed. Cir. 2019) 2164.01(a) , 2164.08
Eon Corp. IP Holdings LLC v. AT&T Mobility LLC, 785 F.3d 616, 114 USPQ2d 1711 (Fed. Cir. 2015) 2106 , 2106.05(b)
Epstein, In re, 32 F.3d 1559, 31 USPQ2d 1817 (Fed. Cir. 1994) 716.07 , 2128 , 2133.03(b) , 2152 , 2152.02(d)
Erlich, Ex parte, 3 USPQ2d 1011 (Bd. Pat. App. & Inter. 1986) 2143.02 , 2173.05(q)
Erlich, Ex parte, 22 USPQ 1463 (Bd. Pat. App. & Inter. 1992) 2124
Ernsthausen v. Nakayama, 1 USPQ2d 1539 (Bd. Pat. App. & Inter. 1985) 2165.01
Estee Lauder, Inc. v. L’Oreal S.A., 129 F.3d 588, 44 USPQ2d 1610 (Fed. Cir. 1997) 2138.05 , 2163
Ethicon Endo-Surgery, Inc. v. Covidien, Inc., 796 F.3d 1312, 115 USPQ2d 1880 (Fed. Cir. 2015) 1504.02
Ethicon, Inc., In re, 844 F.3d 1344, 121 USPQ2d 1139 (Fed. Cir. 2017) 2141
Ethicon, Inc. v. United States Surgical Corp., 135 F.3d 1456, 45 USPQ2d 1545 (Fed. Cir. 1998) 2109.01 , 2181
Ethicon v. Quigg, 849 F.2d 1422, 7 USPQ2d 1152 (Fed. Cir. 1988) 1442.02 , 2242 , 2286 , 2816 , 2821
Etter, In re, 756 F.2d 852, 225 USPQ 1 (Fed. Cir. 1985) 2145 , 2242 , 2258 , 2279 , 2286 , 2816.02
EWP Corp. v. Reliance Universal, Inc., 755 F.2d 898, 225 USPQ 20 (Fed. Cir. 1985) 716.03(b)
Exxon Corp. v. Phillips Petroleum Co., 265 F.3d 1249, 60 USPQ2d 1368 (Fed. Cir. 2001) 601.01(e) , 706.07(h) , 711.01 , 714.01(e) , 714.03
Eynde, In re, 480 F.2d 1364, 178 USPQ 470 (CCPA 1973) 2144.03
EZ Dock v. Schafer Sys., Inc., 276 F.3d 1347, 61 USPQ2d 1289 (Fed. Cir. 2002) 2133.03(e) , 2133.03(e)(4)
Cited authority
- 2111.01 Plain Meaning
- 2012 Reissue Applications Involving Issues of Fraud, Inequitable Conduct, and/or Violation of Duty of Disclosure
- 2173.05(b) Relative Terminology
- 2138.05 “Reduction to Practice”
- 1207.03(a) Determining Whether a Ground of Rejection is New
- 804.02 Avoiding a Double Patenting Rejection
- 2143 Examples of Basic Requirements of a Prima Facie Case of Obviousness
- 2141.03 Level of Ordinary Skill in the Art
- 2144.04 Legal Precedent as Source of Supporting Rationale
- 2190 Prosecution Laches and Res Judicata
- 2305 Requiring a Priority Showing
- 2133.03(a) “Public Use”
- 1481.02 Correction of Named Inventor
- 403.01 Correspondence in Applications
- 403.02 Two Patent Practitioners for Same Application
- 1504.02 Novelty
- 2129 Admissions as Prior Art
- 2172 Subject Matter Which the Inventor or a Joint Inventor Regards as The Invention
- 2411.01 Rejections Based on Deposit Issue
- 2106.05 Eligibility Step 2B: Whether a Claim Amounts to Significantly More
- 2106.05(b) Particular Machine
- 2107.01 General Principles Governing Utility Rejections
- 2138 Pre-AIA 35 U.S.C. 102(g)
- 2144.05 Obviousness of Similar and Overlapping Ranges, Amounts, and Proportions
- 715.05 U.S. Patent or Application Publication Claiming Same Invention
- 715.07 Facts and Documentary Evidence
- 1302.01 General Review of Disclosure
- 2126 Availability of a Document as a “Patent” for Purposes of Rejection Under 35 U.S.C. 102(a) or Pre-AIA 35 U.S.C. 102(a), (b), and (d)
- 2126.01 Date of Availability of a Patent as a Reference
- 2132 Pre-AIA 35 U.S.C. 102(a)
- 2152.02(a) Patented
- 2133.03(b) “On Sale”
- 2121.01 Use of Prior Art in Rejections Where Operability is in Question
- 2106.04(a)(2) Abstract Idea Groupings
- 2106.05(a) Improvements to the Functioning of a Computer or To Any Other Technology or Technical Field
- 2106.05(f) Mere Instructions To Apply An Exception
- 2106.05(g) Insignificant Extra-Solution Activity
- 2106.05(h) Field of Use and Technological Environment
- 2133.03(e)(4) Factors Indicative of an Experimental Purpose
- 2133.03(e)(5) Experimentation and Degree of Supervision and Control
- 2143.02 Reasonable Expectation of Success Is Required
- 2173.05(u) Trademarks or Trade Names in a Claim
- 2301.03 Interfering Subject Matter
- 804 Definition of Double Patenting
- 1490 Disclaimers
- 2144.08 Obviousness of Species When Prior Art Teaches Genus
- 2165 The Best Mode Requirement
- 2165.01 Considerations Relevant to Best Mode
- 2750 Patent Term Extension for Delays at other Agencies under 35 U.S.C. 156
- 2173.05(h) Alternative Limitations
- 2152.02(b) Described in a Printed Publication
- 716.01(d) Weighing Objective Evidence
- 716.02(b) Burden on Applicant
- 716.02(c) Weighing Evidence of Expected and Unexpected Results
- 2141 Examination Guidelines for Determining Obviousness Under 35 U.S.C. 103
- 2142 Legal Concept of Prima Facie Obviousness
- 2144 Supporting a Rejection Under 35 U.S.C. 103
- 608.02(g) Illustration of Prior Art
- 2141.01(a) Analogous and Nonanalogous Art
- 2004 Aids to Compliance With Duty of Disclosure
- 2121.03 Plant Genetics — What Constitutes Enabling Prior Art
- 715.01(a) Reference Is a Patent or Published Application Naming Different Inventive Entity With at Least One Common Inventor
- 715.01(c) Reference Is Publication of Inventor’s Own Invention
- 716.10 Attribution Affidavit or Declaration to Overcome Rejection Under Pre-AIA 35 U.S.C. 102 or 103
- 2155.01 Showing That the Disclosure Was Made by the Inventor or a Joint Inventor
- 2254 Conduct of Ex Parte Reexamination Proceedings
- 2138.06 “Reasonable Diligence”
- 2181 Identifying and Interpreting a 35 U.S.C. 112(f) or Pre-AIA 35 U.S.C. 112, Sixth Paragraph Limitation
- 2106 Patent Subject Matter Eligibility
- 2106.04 Eligibility Step 2A: Whether a Claim is Directed to a Judicial Exception
- 2106.04(a) Abstract Ideas
- 2106.05(d) Well-Understood, Routine, Conventional Activity
- 2106.06(b) Clear Improvement to a Technology or to Computer Functionality
- 2138.03 “By Another Who Has Not Abandoned, Suppressed, or Concealed It”
- 2001.06(c) Information From Related Litigation and/or Trial Proceedings
- 716.04 Long-Felt Need and Failure of Others
- 716.05 Skepticism of Experts
- 2164.06(b) Examples of Enablement Issues — Biological and Chemical Cases
- 2161.01 Computer Programming, Computer Implemented Inventions, and 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2163 Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, “Written Description” Requirement
- 2163.05 Changes to the Scope of Claims
- 2402 The Deposit Rules
- 2164.01(a) Undue Experimentation Factors
- 2164.08 Enablement Commensurate in Scope With the Claims
- 716.07 Inoperability of References
- 2128 “Printed Publications” as Prior Art
- 2152 Detailed Discussion of AIA 35 U.S.C. 102(a) and (b)
- 2152.02(d) On Sale
- 2173.05(q) “Use” Claims
- 2124 Exception to the Rule That the Reference Must be Prior Art
- 2109 Inventorship
- 1442.02 Concurrent Litigation or Trial Before the Patent Trial and Appeal Board
- 2242 Criteria for Deciding Request Filed under 35 U.S.C. 302
- 2286 Ex Parte Reexamination and Litigation Proceedings
- 2816 Determination on the Request
- 2821 Multiple Post-Patent Office Proceedings
- 2145 Consideration of Applicant’s Rebuttal Arguments and Evidence
- 2258 Scope of Ex Parte Reexamination
- 2279 Appeal to Courts
- 2816.02 Criteria for Making the Determination
- 716.03(b) Commercial Success Derived From Claimed Invention
- 601.01(e) Nonprovisional Application Filed Without at Least One Claim
- 706.07(h) Request for Continued Examination (RCE) Practice
- 711.01 Express or Formal Abandonment
- 714.01(e) Amendments Before First Office Action
- 714.03 Amendments Not Fully Responsive, Action To Be Taken
- 2144.03 Reliance on Common Knowledge in the Art or “Well Known” Prior Art
- 2133.03(e) Permitted Activity; Experimental Use